DeepCyte Inc.

DeepCyte Inc. , based in the US, focuses on advancing predictive toxicology through its innovative platform, DeeImmuno, which integrates single-cell metabolomics with AI to evaluate drug toxicity effectively. DeepCyte Inc. operates in the field of predictive toxicology, providing insights into drug safety.

Founded in 2025 and headquartered in Wilmington, US, the company recently completed a SEED funding round in April 2026, raising USD 1. 5 mn, which is the total amount raised to date. The firm has completed a total of 1 deal, targeting pharmaceutical companies for its innovative services. The founder's history is not documented in the provided information.

DeepCyte specializes in predictive toxicology through its innovative product, DeeImmuno, which combines single-cell metabolomics with artificial intelligence (AI) to assess drug toxicity at the cellular level. This advanced technology enables the detection of metabolic changes within individual immune cells, offering insights into the mechanisms that underlie toxic effects. DeeImmuno does not simply provide a toxicity risk score; it reveals the intracellular processes altered by drug exposure, thus assisting pharmaceutical companies in making informed decisions during drug development. The primary users of DeepCyte's solutions include pharmaceutical companies engaged in drug discovery and development, particularly those focused on addressing the significant challenge of drug-related toxicity.

DeepCyte's offerings are geared toward clients in various global markets, including North America and Europe, where regulatory demands for drug safety are paramount. Revenue generation for DeepCyte occurs through a subscription model or partnerships with pharmaceutical companies utilizing its DeeImmuno platform. Clients engage in transactions that involve access to the service based on specific project parameters or ongoing collaborations, providing continuous insights into drug safety and efficacy. The company’s flagship product, DeeImmuno, is designed to cater to organizations aiming to mitigate the high costs and risks associated with clinical trial failures due to toxicity, with a pricing structure reflecting the value of actionable mechanistic insights provided.

In April 2026, DeepCyte Inc. raised USD 1. 5 mn in Seed funding from unspecified investors. The company plans to utilize this funding to scale its operations and further develop its analysis platform and predictive AI tools.

Upcoming strategies involve the introduction of new products aimed at enhancing predictive capabilities, as well as an expansion into additional global markets to meet increasing regulatory standards for drug safety.